Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Opioid Treatment topic
No spam. Unsubscribe anytime.
Senate panel bars prior authorization for most medication‑assisted opioid treatment
Summary
HB 16‑56 removes prior‑authorization requirements for many pill‑ and film‑based medication‑assisted treatments (buprenorphine formulations), while preserving prior authorization for injectable treatments; the committee adopted an amendment to address Medicaid rebate concerns and gave Medicaid until January to comply.
The Senate Insurance & Commerce Committee passed House Bill 16‑56, a measure designed to reduce barriers to medication‑assisted treatment (MAT) for opioid dependence by restricting insurers and Medicaid from requiring prior authorization for certain MAT prescriptions.
Representative Ferguson, the sponsor, said the bill aims to make it easier and faster for patients to start treatment. She cited House testimony in which a pregnant patient missed a required meeting and was denied prior authorization to continue treatment late in pregnancy. "When someone comes in and they're ready for treatment, you really need to get them into treatment as soon as possible," Ferguson said.
The committee adopted an amendment to keep prior authorization for injectable MAT formulations because of cost concerns, and to give Medicaid until January to resolve rebate‑program issues. David Roden of the Arkansas Medical Society clarified that an amendment referencing drugs "approved by the United States Food and Drug Administration" means only FDA‑approved drugs qualify as MAT under the bill.
Committee members asked for clarifications about definitions and scope. After discussion the committee voted to pass the bill (motion by Senator Elliott; second by Senator Irvin). The transcript records voice votes; no roll‑call tally appears in the hearing record.
Why it matters: Sponsors said removing prior authorization for many MAT prescriptions could reduce delays that block timely treatment for patients dependent on opioids, including pregnant patients.
Next steps: The bill cleared committee; the transcript does not list a floor schedule or final implementation dates.
